- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01679028
Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese
Single- and Multiple- Dose-Escalation Study to Investigate the Safety and Tolerability of T89 in Japanese Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single centre, double-blind, randomized, placebo controlled, single- and multiple- dose-escalation study.
After informed consent is obtained, subjects were evaluated with a medical history questionnaire, physical examination, blood and urine collections for clinical laboratory safety tests, urine drug screen, serum pregnancy test for each women, vital signs and ECG. The subjects who fulfill the inclusion criteria but no exclusion criteria were provisionally enrolled. For participation in this trial, subjects were instructed to avoid any prescription, over-the-counter (OTC), and alternative / complementary medications or significant changes in diet without advance permission from principal investigator. The subjects were instructed to discontinue alcohol, caffeine and bromine containing beverage/food. 20 subjects were enrolled and divided into three Groups: Group A, Group B and Group C.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Glendale, California, United States, 91206
- California Clinical Trial Medical Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female volunteers aged between 20-55 years.
- First generation of Japanese, and live in the U.S.A. less than 5 years and maintained Japanese lifestyle.
- The body mass index between 18 and 30 kg/m2.
- Willing to not take alcoholic beverages, and caffeine- and the bromine-containing beverages and foods (e.g., tea, coffee, chocolate, cola, etc.) for the duration of the study beginning at the screening visit.
- ECG with no clinically significant abnormalities.
- No clinically significant medical history.
- Vital signs and laboratory tests with no clinically significant abnormalities.
- Volunteers had not taken any medication that would interfere with the procedures or interpretation of study data or compromise subject safety within 4 weeks prior to the first dose, per principal investigator discretion.
- Volunteers must understand and be willing, able and likely to comply with all study procedures and restrictions.
- Volunteers must be able to give voluntary written informed consent.
Exclusion Criteria:
- History of uncontrolled, clinically significant neurologic, cardiovascular, haematological, pulmonary, hepatic, renal, metabolic, GI, urologic, immunologic, endocrine or psychiatric disease.
- Pregnant or nursing mother - Women of childbearing potential must have a negative pregnancy test, not be breast feeding and be established on a method of contraception that in the investigator's opinion is acceptable.
- Have on-going other treatment or medicine that may interfere with T89 or administration of similar medication within 2 weeks of entering study, per principal investigator discretion.
- Blood donor in recent 3 months.
- Have taken part in other clinical trials involving administration of study medications in the previous 1 month before participation.
- Excessive alcohol use (habitually consumed more than 21 units of alcohol per week or has a history of alcohol abuse as defined by DSM-IV-TR criteria (a unit of alcohol is equal to 1 ounce of hard liquor, 5 ounces of wine or 8 ounces of beer within past two years).
- History or evidence of habitual use of tobacco or nicotine containing products within 3 months of Screening, with the exception of light smoking (up to 5 cigarettes per day or the equivalent)
- Known hypersensitivity to any of the ingredients of T89 or other relevant drug allergy.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Group A
150mg Placebo Single dose
|
150mg single dose
|
Experimental: T89 Group A
150mg T89 single dose
|
150mg single dose on day 1
Other Names:
|
Placebo Comparator: Placebo Group B
300mg placebo single dose
|
300mg single dose
|
Experimental: T89 Group B
300mg T89 single dose
|
300mg single dose
Other Names:
|
Placebo Comparator: Placebo Group C
225mg Placebo bid for 14 days
|
225mg bid
|
Experimental: T89 Group C
225mg T89 bid for 14 days
|
225mg bid
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Drug Events and Serious Adverse Events
Time Frame: 30 days (after first dosing)
|
the Incidence of Adverse Drug Events and serious adverse events
|
30 days (after first dosing)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Jason GUO, M.D., Tasly Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- T89-10-JP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo Group A
-
AnGes, Inc.Japan Agency for Medical Research and DevelopmentCompleted
-
National Research Council, SpainUniversidad Católica San Antonio de Murcia; The Scientific and Technological...Completed
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanCompleted
-
Loma Linda UniversityTerminatedType 1 Diabetes Mellitus
-
Contera PharmaBukwang PharmaceuticalActive, not recruitingDyskinesiasFrance, Germany, Italy, Korea, Republic of, Spain
-
Benha UniversityRecruiting
-
Loyola UniversityUnknown
-
Shanghai Fosun Pharmaceutical Industrial Development...RecruitingNeurofibromatosis 1 | NF1 | Plexiform NeurofibromaChina
-
Zhejiang UniversityUnknownHyperlipoproteinemiaChina
-
Sana'a UniversityUniversity of Malaya; Ministry of Health, MalaysiaCompletedAnemia | Malnutrition | Intestinal Parasitic InfectionsMalaysia